press releases

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune January 06, 2016 08:24 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) filed a premarket approval (PMA) supplement application for its new,… Read More

January 04, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Jan. 13, 2016, in San Francisco. Bill Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Read More

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone EF-14 trial results supported recent FDA approval of Optune for newly diagnosed GBM December 15, 2015 11:01 AM Eastern Standard Time… Read More

December 15, 2015 11:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the American Medical Association (JAMA). Read More

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells December 14, 2015 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–New preclinical data on Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy revealed a more thorough… Read More

Removal of FDA contraindication increases addressable GBM patient population December 03, 2015 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–A retrospective analysis of Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable… Read More

December 02, 2015 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure (NASDAQ: NVCR), show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung… Read More

Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone November 20, 2015 04:01 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today new Phase 3 data showing that glioblastoma patients… Read More

Quality of life was maintained throughout treatment with Tumor Treating Fields EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who received chemotherapy alone November 17, 2015 07:00 AM Eastern Standard Time… Read More